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Background: The efficacy and toxicity of first line palliative chemotherapy for soft tissue sarcomas (STS) in the
elderly is poorly described.
Methods: Patients over the age of 65 years receiving first line chemotherapy for advanced non-GIST STS January
1998 - January 2012 at the Royal Marsden Hospital were identified. Data regarding survival and predictive factors
were collected retrospectively.
Results: 120 patients (52 females) with a median age of 72 (range 65–83) were treated. The most common
histological subtypes were undifferentiated sarcoma (30%), leiomyosarcoma (27%), angiosarcoma (14%). 42% of
patients had high grade tumours. 70% of patients had metastatic disease at presentation; lung metastasis being
the most common disease site (72%). 80% received single agent chemotherapy, mostly with doxorubicin (60%).
The median number of cycles was 2 (IQR 3). A partial response was reported in 20% of patients with disease
stabilisation in a further 20%. 38% of patients were hospitalised for chemotherapy related toxicity. The median
overall survival (OS) was 6.5 months (95% CI 4.7-8.3). Anaemia, lymphopenia, hypoalbuminemia, sarcoma subtype
and co-morbidities were predictive for overall survival.
Conclusion: The overall survival for elderly patients with STS is poor but several predictive factors have been
identified. Hospital admissions for chemotherapy related toxicity are common.
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Soft tissue sarcoma (STS) encompasses a wide spectrum
of malignant tumours of mesenchymal origin with vari-
able clinical behaviour. Optimal treatment for those with
localised disease is surgery. However, up to half of these
patients will later present with metastatic disease. Others
present de-novo with locally advanced or metastatic
disease which is not amenable to surgical resection. Over
40% of STS are diagnosed in people older than 65 years
of age. Patients with inoperable STS have a poor prog-
nosis with a median survival of 12 months or less [1].
The mainstay of treatment for these patients is palliative
chemotherapy which has been shown to be beneficial in
approximately one half of patients with metastatic STS
[1]. Advancing age has been shown to be an independent* Correspondence: Charlotte.benson@rmh.nhs.uk
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static STS [1-3]. However, elderly patients are under-
represented in clinical trials. A recent analysis of 2636
patient in first line EORTC trials for STS, found only 274
over 65 and 16 over aged over 75 [4]. As such, the efficacy
and toxicity of first line palliative chemotherapy for STS
in the elderly is poorly described.
We conducted this retrospective study with the aim of
describing the efficacy and toxicity associated with first
line chemotherapy for advanced STS in an unselected
cohort of patients over the age of 65 years treated at a
single institution. We aimed to identify predictive prog-
nostic factors.Methods
Patients over the age of 65 years diagnosed with STS
from January 1998 - January 2012 at the Royal MarsdenThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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sarcoma database.
Only patients with a primary tumour not amenable
to surgical resection or those with metastatic disease
were included. All patients receiving first line palliative
chemotherapy at our institution were included. Pa-
tients with gastro intestinal stromal tumour (GIST)
were excluded.
Data regarding each patient were retrospectively col-
lected from electronic patient records. Date of diagnosis,
age at diagnosis, site of metastasis, chemotherapy agents
used, dose reductions, hospital admission during treat-
ment, performance status, serum albumin, sodium, LDH,
lymphocyte count, platelet count, date of death or last
follow-up were collected. Data on co-morbidities was also
collected and the Age Adjusted Charlson Co-morbidity
Index (AACCI) [5] for each patient was calculated. How-
ever, as locally advanced/metastatic sarcoma was the
disease of interest (rather than a co-morbidity) it was ex-
cluded from the score. A higher score was indicative of a
greater number of co-morbidities. The clinical outcome of
each patient was recorded as alive or dead as of 31st of
January 2013. Response to treatment was recorded by
retrospective review of radiology reports as per Response
Evaluation Criteria in Solid Tumors. Patients were re-
imaged every 2–3 cycles or earlier if there was clinical sus-
picion of disease progression.
The study proposal was reviewed and approved by The
Royal Marsden Hospital Institutional Audit Committee.
Statistics
The primary end point was overall survival. The secondary
endpoints were response to treatment, admission to hos-
pital secondary to chemotherapy toxicity and exploration of
prognostic factors.
Overall survival was measured from the start of
chemotherapy to the time of death and censored at last
follow-up using the Kaplan-Meier methodology.
The effect of age, histologic subtype, grade, site of meta-
static disease, blood parameters and AACCI on response to
chemotherapy and hospital admission secondary to chemo-
therapy toxicity was investigated in univariate analysis by
means of the χ2 test, Fisher exact test, Mann–Whitney test
and Kruskall-Wallis one way ANOVA. Laboratory ranges
for blood parameters were as follows; serum albumin
(normal range 35 – 50 g/L), sodium (normal range 135 –
145 mmol/L), LDH (normal range 98–192 U/L), lympho-
cytes (normal range 1.3 – 3.5 × 109/L), platelets (normal
range 150 – 400 × 109/L), and haemoglobin (normal
range, male 13 – 18 g/dL, female 11.5 – 15.5 g/dl).
A Univariate log-rank analysis was used to investigate
these parameters as potential prognostic factors. Multi-
variate analysis was not performed due to small numbers
in subgroups.Results
We identified a total for 220 patients ages 65 or over
with non-GIST STS between January 1998 to January
2012. 24 patients were excluded as they attended our in-
stitution for a second opinion only and 76 patients were
excluded as they did not receive chemotherapy. 120 pa-
tients (53 (44%) females) with a median age of 72 (range
65–83) were treated and eligible for inclusion in this study.
The most common histological subtypes were undiffer-
entiated sarcoma (30%), leiomyosarcoma (27%), angiosar-
coma (14%), liposarcoma (8%), rhabdomyosarcoma (7%)
and myofibroblastic tumour (7%). 82 (68%) patients had
previous surgical resection with or without radiotherapy
for treatment of localised sarcoma. 36 (30%) patients
received chemotherapy for locally advanced disease; the
remainder had metastatic disease at presentation. Demo-
graphic data is shown in Table 1. Lymphopenia at the end
of chemotherapy was reversed in only in 2 patients (a
patient who progressed after 2 cycles of treatment and an-
other with stable disease). Only 1 patient showed a clinic-
ally significant improvement in albumin (but progressed
after 2 cycles).
Survival
At the time of analysis 9 patients were still alive. The
median overall survival (OS) was 6.5 months (95% CI
4.7-8.3; range 0 – 106) Figure 1. 2 (1.5%) patients died
within 30 days of receiving chemotherapy. Univariate
analysis revealed lymphocyte count (p = 0.003), albumin
(p = 0.003), haemoglobin (p = 0.02), histological subtype
(p = 0.02) and AACI (p = 0.03) were predictive of OS
(See Table 2).
Response and toxicity
97 patients (80%) received single agent chemotherapy,
most commonly doxorubicin (n = 61) followed by pacli-
taxel (n = 16). The most common combination chemo-
therapy regimens were gemcitabine and docetaxel (n = 8)
and doxorubicin and ifosfamide (n = 6). The median num-
ber of cycles received was 2 (range 1–11). A partial re-
sponse was reported in 20% of patients, with disease
stabilisation in a further 20% (clinical benefit). Univariate
analysis did not identify any factors predictive for response
to chemotherapy.
38% of patients were hospitalised for chemotherapy re-
lated toxicity. Univariate analysis identified only serum al-
bumin as a predictive factor for hospital admission due to
toxicity. 32% of patients with a low albumin were admitted
to hospital for chemotherapy related toxicity, compared to
24% of patients with a normal serum albumin (p = 0.02).
Discussion
In this retrospective analysis of real world data from 120
older patients undergoing palliative chemotherapy for





Median age (range) in
years
73 (65–86)
Histology Rhabdomyosarcoma 8 6.7
Angiosarcoma 17 14.2
Liposarcoma 10 8.3





Disease status Locally advanced 36 30
Metastatic 84 70
















LDH > 250U/L 71 59.2
Lymphopenia (<1×109/L) 34 28.3
Hypoalbuminemia (<35 g/L) 48 40
*Haemoglobin < 13 g/L for males, <11.5 g/L females.
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group of patients is poor. Previously reported data from
our own institution in patients under the age of 65
showed a median OS of around 1 year [1]. Synovial and
liposarcomas represented almost a quarter of this cohort
and were found to be independently associated with
better survival. In our older cohort, these subtypes
accounted for less than 10% of patients and therefore
their absence may contribute to the poor survival. We
also found that other aspects of tumour histology were
an important determinant of prognosis in this elderly
population. In particular, median overall survival wassignificantly better for patients with leiomyosarcomas
(10.1 months) and angiosarcomas (9.7) when compared
to undifferentiated sarcomas (3.7). This difference was
statistically (p = 0.02) and clinically significant and likely
reflects differences in the underlying nature of these dis-
eases, and their variation across differing age groups.
Undifferentiated sarcoma is often highly aggressive and
sometimes resistant to treatment while conversely, the
angiosarcoma frequently observed in older patients affects
the scalp and face, responds to treatment with paclitaxel
and liposomal doxorubicin and may remain relatively
localised for many months.
A recent analysis of 274 patients aged over 65 with
STS treated with first line chemotherapy within EORTC
trials was presented at the 2014 European Society of
Medical Oncologists Congress [4]. These patients had a
median survival of 9.8 months, but the population dif-
fered from ours in that patients were slightly younger
(median 68 versus 72 years), with a larger proportion of
leiomyosarcomas and were likely to be of a better per-
formance status (more than 85% with a PS of 0–1), since
they were patients who had been recruited into clinical
trials. Patients with significant co-morbidities are often
excluded from clinical trials. We found that more co-
morbidity, as assessed by the AACCI was associated
with worse OS. This has been reported in other tumour
types [6-8] and may be because patients with multiple
co-morbidities tolerate chemotherapy less well, or are
perhaps sub-optimally treated [9].
Functional capabilities and nutritional status [10]
alongside laboratory markers have been shown to pre-
dict for survival in older patients [11]. We were unable
to gather data regarding the functional ability of patients
treated but found a number of laboratory markers to
predict for survival. In keeping with previous reports we
found that around a quarter of this cohort of patients
with advanced STC were lymphopenic and this was
associated with worse survival [12]. As the rate of lym-
phopenia in this elderly population is similar to that
previous reported in patients with advanced STS, age re-
lated reductions in thymic function are unlikely to be
the explanation [13]. Lymphopenia may be an indicator
of decreased self-renewal capacity of hematopoietic stem
cells thereby contributing to impaired immune function
[14] or may also reflect tumour related immunosuppres-
sion [15]. Anaemia and hypoalbuminemia in malignancy
may be indicative of malnutrition but also reflect a com-
plex tumour related inflammatory cytokine response
[16-18]. We collected lymphocyte count and albumin at
the end of treatment but found that in the vast majority
of patients, even in those that responded to treatment,
these markers did not improve. It is difficult to interpret
this data but may be related to the overall poor progno-
sis in this patient group.
Figure 1 Kaplan Meier curve for overall survival.
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chemotherapy agents on toxicity, response or survival
due to the heterogeneity of regimes used. Previous data
from our institute in younger patients showed that
doublet chemotherapy improved overall survival [1], al-
though this has not been demonstrated in prospective
phase 3 studies [19-21]. Only a few single arm studies
have specifically investigated tolerability and efficacy of
specific chemotherapy regimes in the elderly patients
with STS. A small study of daily oral metronomic cyclo-
phosphamide and prednisolone in elderly patients with
unresectable STS showed good tolerability and a response
rate of almost 27% [22]. Also a retrospective analysis of
patients with head and neck angiosarcoma (mainly an eld-
erly population), showed a response rate of greater than
80% and good tolerability [23].
We were unable to identify factors associated with
response perhaps because of the smaller number of
patients in our study, or perhaps because sarcomas are a
heterogonous group of disease with many displaying in-
trinsic chemotherapy resistance.
We used hospitalisation as a surrogate marker for
chemotherapy toxicity and found that over one third of
patients were admitted to hospital while undergoing
chemotherapy. This is not inconsistent with other data
in this age group. A study of patients over the age of 75
undergoing palliative chemotherapy for bowel cancer
demonstrated that 42% of patients suffered grade 3 or 4
toxicity [24]. We found that low albumin (possibly due
to advanced disease, tumour cachexia or malnutrition)
was associated with an increased risk of hospitalisation.
Low albumin is known to affect the volume of distribu-
tion of chemotherapy drugs and therefore in part thereis likely to be a pharmacokinetic explanation for this
finding [25].
Comprehensive Geriatric Assessment (CGA) is defined
as a multidimensional, interdisciplinary diagnostic process
focusing on determining an older person’s co-morbidities,
psychosocial, and functional capabilities to develop a coor-
dinated and integrated plan for treatment and long-term
follow-up [26]. CGA can detect problems commonly
missed in routine clinical assessment [27] in up to 50% of
geriatric patients [28] and have been shown to be more
sensitive at selecting frail patients than physicians
judgement [29]. This could allow for optimisation of
co-morbidities prior to assessing older patients for
chemotherapy. As age is an independent risk factor for
anthracycline induced cardiomyopathy [30] we have
adopted an approach of optimising cardiovascular
health with cardio-oncology input prior to administra-
tion of anthracylines and/or considering liposomal
doxorubicin [31].
Despite the potential value, the main limitation to in-
corporating CGA in oncology clinics is that it requires
time and service development. Furthermore, there is a
lack of randomised studies to assess the effectiveness of
CGA in selecting patient for active oncology treatment
versus best supportive care. Attempts have been made
to simplify the process of CGA and develop tools
incorporating geriatric assessment variables which can
be used in clinics. Two large prospective studies [32,33]
have demonstrated that scores including geriatric as-
sessment variables have moderate ability to predict
for chemotherapy related toxicity and are more sensi-
tive than PS alone [32]. Despite acknowledging the
current limitations, The International Society of Geriatric
Table 2 Univariate analysis




Sex male 5.4 (3.1 – 7.7) 0.2
female 6.3 (3.5 – 9.1)
Age <75 years 6.5 (4.6 – 8.4) 0.3
>75 years 5.3 (3.9 – 6.6)
LDH normal 7.1 (4.6 – 9.7) 0.3
high 5.4 (3.5 – 7.3)
Lymphocytes normal 7.8 (5.9 – 9.5) 0.003*
low 3.7 (1.8 - 5.6)
Sodium normal 5.8 (4.4 – 7.2) 0.8
low 8.2 (4.2 – 12.3)
Albumin normal 7.7 (4.9 – 10.5) 0.003*
low 3.1 (0.9 – 5.1)
Haemoglobin normal 8.1 (5.7 – 10.5) 0.02*
5.3 (3.7 – 6.9)
Grade low 6.0 (4.5 – 7.6) 0.9
intermediate 7.5 (6.8 – 8.1)
high 6.3 (4.8 – 7.9)
Histological subtype leiomyosarcoma 10.1 (3.9 – 16.4) 0.02*
angiosarcoma 9.7 (6.4 – 12.9)
undifferentiated 3.7 (1.2 – 6.2)
other 5.1 (2.9 – 7.2)
Sites of visceral involvement Lungs 5.7 (4.5 – 7.1) 0.2
Liver 10.1 (0 – 30.9)
bone 6.3 (0.9 – 11.7)
Age Adjusted Charlson Index <3 9.6 (4.4 – 14.9) 0.03*
>3 5.6 (3.8 – 7.4)
*significant factors in univariate analysis. Laboratory ranges for blood parameters were as follows; serum albumin (normal range 35 – 50 g/L), sodium (normal
range 135 – 145 mmol/L) lymphocytes (normal range 1 – 3.5 × 109/L), platelets (normal range 150 – 400 × 109/L) , LDH (normal range 100 – 250 U/L) and
haemoglobin (normal range, male 13 – 18 g/dL, female 11.5 – 15.5 g/dl).
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management of elderly patients with cancer [26].
Our key limitations are those of any retrospective ana-
lysis. Data on performance status, weight and specific
chemotherapy toxicity were poorly documented and
therefore we were unable to assess the effect of these on
survival and response.
Older patients with STS have a poor prognosis. Some
do benefit from palliative chemotherapy however there
is also a high risk of significant toxicity. Selecting appro-
priate patients to undergo treatment is complex and de-
pendant on several factors including sarcoma subtype,
co-morbidities and a number of biomarkers that prob-
ably reflect disease burden, such as performance status,
low albumin, anaemia etc. These challenges remain,
even in an age of targeted therapies as many of these
can cause cardiovascular complications [34]. Optimisingthe management of older people with cancer by develop-
ing a robust assessment process and evidence base is im-
perative. Older patients should be recruited to clinical
trials and in some instances specific clinical trials for
elderly patients with co-morbidities are warranted.
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